U.S. Markets closed

ACADIA pimavanserin chances of success have improved, says Roth Capital

Roth Capital believes that a recent article in the journal Schizophrenia Research could increase use of ACADIA's pimavanserin as an off-label schizophrenia treatment. The firm thinks that changes made to the current study of the drug compared with previous studies should cause it to yield statistically significant results, and Roth maintains a $3 target and Buy rating on the shares.